Clinical Trial Update: Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial updates efficacy and safety of BST-236 in newly diagnosed acute myeloid leukemia patients unfit for standard induction therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• BST-236

Snippet

Sponsor: BioSight Ltd. | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED